Autosomal Dominant Nocturnal Frontal Lobe Epilepsy When Carbamazepine Has Not Controlled Seizures
Carbamazepine is the established drug of choice for NFLE/ADNFLE. When it does not achieve adequate nocturnal seizure control, a defined next-line approach applies — with specific alternative and add-on antiepileptic options supported by clinical evidence.
First-line treatment failure
Carbamazepine — the drug of choice in NFLE/ADNFLE — is considered to have failed when it does not result in abolition of nocturnal seizures, or when it does not produce at least a 50 % reduction in nocturnal seizure frequency. This failure condition defines the indication for the next treatment line.
Next-line approach — partial overview
When carbamazepine is insufficient, the next step involves selected alternative antiepileptic agents or add-on strategies — the complete list of options, selection criteria, and clinical sequencing are laid out in the full protocol.
Clinical goal: Seizure freedom, or at minimum a ≥ 50 % reduction in nocturnal seizure frequency.
References
DOI: 10.1007/s11910-013-0424-6
- Topiramate administered as single or add-on therapy from 50 to 300 mg daily at bedtime was found to be effective in about 90 % of cases in a small series of 24 NFLE patients.
- Oxcarbamazepine (at a mean dose of 30.4 ±11.7 mg/kg/day) fully controlled nocturnal seizures in a single study on eight children between the age of 4 and 16 years with NFLE (some of whom were refractory to previous antiepileptic medications).
- Varadkar et al. reported a reduction or complete control of nocturnal seizures in three members of an ADNFLE family with acetazolamide, 500 mg at night, as add-on therapy to carbamazepine.
- Treatment with nicotine transdermal patches had a beneficial effect on seizure frequency in a single patient with ADNFLE, whose seizures were refractory to standard antiepileptic drugs.
View source ↗